TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...

The forces shaping the launch environment are likely to increase competitive pressure, with more targeted medicines in narrower indications and more tightly defined markets.